GENFIT highlighted its extensive scientific presence at the EASL Congress 2026, focusing on Acute on-Chronic Liver Failure (ACLF), non-invasive diagnostics for MASH, and progress in Primary Biliary Cholangitis (PBC) through its partner Ipsen. The company presented seven posters on ACLF and real-world data, emphasizing ACLF as a strategic priority with global efforts to harmonize its definition. GENFIT's diagnostic technology NIS2+® is gaining importance amid expanding MASH treatments. Ipsen shared new data on Iqirvo® (elafibranor) for PBC, reinforcing GENFIT's growing impact in liver disease therapies. This event underscores GENFIT's role in advancing liver disease research and patient care globally.
Peec AI, an AI search analytics platform, surpassed $10 million in annual recurring revenue just 16 months after launch, doubling revenue in the last five months. The company is expanding rapidly, opening its first US office in New York to meet growi...
The National Crime Prevention Council (NCPC) has called on lawmakers to reject the House's Kids Internet and Digital Safety Act (H.R. 7757), criticizing it as insufficient for protecting children online. NCPC argues the bill weakens state powers and ...
Fannie Mae has started marketing a sale of approximately 2,333 reperforming loans with an unpaid principal balance of about $565 million. These loans were previously delinquent but have since become current. Buyers must offer loss mitigation options,...
Shares of Unusual Machines Inc. (UMAC), where Donald Trump Jr. is a shareholder and board member, surged after reports that the Pentagon is discussing direct financial support and equity stakes in domestic drone manufacturers. The funding talks invol...
REalloys has signed a 15-year agreement to secure 15% of Phase 1 production from the Tanbreez heavy rare earth project in Greenland, one of the largest Western-aligned deposits. This deal strengthens US efforts to reduce dependence on Chinese rare ea...
